Cytokinetics, Incorporated (CYTK)

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

No competitor list for this company yet.

• 3/9/2026POSITIVE
  Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market

  A significant insider transaction at Cytokinetics Inc. has been reported, with an executive exercising stock options valued at over $920,000. This occurs as the company's cardiac drug candidate progresses towards market entry. The exercise of options by an insider often signals confidence in the company's future prospects and the value of its stock. Coupled with the impending market launch of a key therapeutic, this event suggests positive momentum for Cytokinetics, potentially attracting further investor interest and supporting share price appreciation.

• 2/24/2026NEUTRAL
  Cytokinetics (CYTK) Q4 2025 Earnings Transcript

  The financial community is keenly awaiting the Q4 2025 earnings transcript from Cytokinetics (CYTK). While specific details are not yet available, the analysis of such documents is crucial for investors looking to assess the biopharmaceutical company's operational performance and future prospects. Transcripts offer direct insights into management discussions regarding financial results, drug pipeline advancements, and growth strategies. Analysts will closely monitor any indications concerning key drugs like omecamtiv mecarbil or aficamten, as well as projections for the current fiscal year. The current lack of specific data suggests a cautious approach, but the release is a standard event providing transparency and a basis for informed decisions.